TLDR Biotech
The top stories in biotech & pharma, straight to your inbox in only one email. Trusted by 2500+ biotech and pharma professionals.
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | February 10 - 11, 2026
🧬 Madrigal Pharmaceuticals and Suzhou Ribo Life Science partner on MASH siRNA programs for $60M upfront + $4.4B biobucks, GSK and Teva quietly settle decade-long Coreg skinny label patent dispute over heart medication, Fujifilm Biotechnologies announces £400M ($545.3M) UK biomanufacturing expansion adding 19,000 liters single-use capacity for medicines and vaccines, Gubra launches Gubra Ventures with Zoë Johnson leading new independent biotech company creation unit, Nektar Therapeutics raises $400M public offering for clinical development and manufacturing costs, FDA approves Merck & Co.'s Keytruda (pembrolizumab) for PD-L1 positive platinum-resistant ovarian carcinoma second-line treatment, Takeda consolidates Boston operations by subleasing 630K square feet while opening new Cambridge R&D facility
Biotech & Pharma Updates | February 9 - 10, 2026
🧬 Moderna, Mexico sign five-year manufacturing pact for respiratory vaccine supply and technology transfer, Kainova Therapeutics raises $32M CAD ($23.6M) Series B - accelerating immuno-oncology and inflammation therapies, Kailera Therapeutics and Hengrui advance ribupatide for obesity to Ph3 following positive Ph2 results in China, Insilico Medicine + China Medical System partner on AI-driven CNS, autoimmune drug development for up to $9M per programme, PharmaEssentia to build $46M manufacturing plant in Puerto Rico for rare blood disease treatment Besremi
Biotech & Pharma Updates | February 8 - 9, 2026
🧬 Eli Lilly to acquire Orna Therapeutics for $2.4B for their in vivo CAR T tech - targeting autoimmunity, QuantX Biosciences raises $85M Series B for computational drug discovery platform, Aerska raises $39M Series A - developing brain shuttle technology for RNA medicines, Takeda + Iambic partner on AI drug discovery for oncology and inflammatory diseases - $1.7B+ milestones, Bristol Myers Squibb + Evinova partner on AI clinical development platform to improve efficiency and cut costs, Basilea Pharmaceutica receives $5M milestone payment from Pfizer for strong Cresemba sales in Asia Pacific
Biotech & Pharma Updates | February 5 - 8, 2026
🧬 Agomab Therapeutics + SpyGlass Pharma collectively raise $350M IPOs, inflammatory/ophthalmic treatments, Eli Lilly+ Innovent Biologics partner on oncology immunology development - $350M upfront + $8.5B milestones, GSK's Nucala (mepolizumab) wins European Commission approval for chronic obstructive pulmonary disease following Ph3 trial, Genentech's fenebrutinib (fenebrutinib) shows superiority over Ocrevus in Ph3 trial for primary progressive multiple sclerosis
Biotech & Pharma Updates | February 4 - 5, 2026
🧬 Veradermics raises $256M IPO developing oral version of Rogaine molecule, Angitia Biopharmaceuticals raises $130M Series D for bone disease bispecific antibodies development, Ginkgo Bioworks + OpenAI collaborate on autonomous laboratory achieving 40% cost reduction in cell-free protein synthesis using GPT-5, Bayer's asundexian (factor XIa inhibitor) shows 26% stroke recurrence reduction in Ph3 secondary stroke prevention trial, TrumpRx government pharmaceutical platform launches with discounted drugs from big pharma names
Biotech & Pharma Updates | February 3 - 4, 2026
🧬 Novartis CEO projects 2026 growth despite massive $4B patent cliff-caused revenue hole, Nanologica acquires Ardena's Syntagon API facility for $961K - adding 45 employees in Sweden expansion, Third Arc Bio raises $52M Series A extension for oncology/immunology antibodies, Eli Lilly's Zepbound (tirzepatide) plus Taltz combo meets Ph3b endpoints in psoriatic arthritis, Evogene + Shanghai Lishan Biopharmaceuticals license BMC128 microbiome therapeutic for renal and lung cancer, OXB, Bristol Myers Squibb expand partnership for commercial lentiviral vector manufacturing for CAR-T therapies, President Trump signs spending bill reauthorizing rare pediatric disease vouchers - ending uncertainty for rare disease developers
Biotech & Pharma Updates | February 2 - 3, 2026
🧬 Merck & Co. projects $70B+ annual revenue opportunities by mid-2030s - preparing for post-Keytruda future with expanded pipeline, AccurEdit Therapeutics raises $75M Series A to advance CRISPR gene editing pipeline, FDA announces flexible regulatory approach to shepherd CAR-T therapies for autoimmune diseases development, Insilico Medicine receives $5M milestone from Menarini Group for MEN2501 first-in-human dosing achievement, NIH Director Bhattacharya acknowledges no vaccine-autism link amid Senate hearing on agency modernization efforts, Veradermics prices upsized $256M IPO for dermatological and aesthetic therapeutics development, Pfizer's PF-08653944 demonstrates 12.3% weight loss in Ph2 trial for obesity with monthly GLP-1 receptor agonist dosing
Biotech & Pharma Updates | February 1 - 2, 2026
🧬 Novo Nordisk's CagriSema (semaglutide/cagrilintide) tops semaglutide in Ph3 type 2 diabetes trial targeting GLP-1/amylin pathways, Sanofi's venglustat (glucosylceramide synthase inhibitor) hits Ph3 goal in Gaucher disease but misses in Fabry disease, Vaxcyte raises $632.5M public offering - clinical-stage vaccine innovation company, Newsoara + vTv Therapeutics expand partnership for global HPP737 inflammation drug rights with $135M total deal value, Roche + SanegeneBio partner on RNAi programme - $200M upfront + $1.5B milestones
Biotech & Pharma Updates | January 29 - February 1, 2026
🧬 Eli Lilly picks Pennsylvania for fourth US manufacturing site in $27B domestic expansion push, AstraZeneca + CSPC Pharmaceutical partner on obesity drugs - $1.2B upfront + $18.5B biobucks, CDMO Vetter Pharma invests €480M ($574.4M) for new German production facility - targeting 2031 launch with 2,000 jobs, Lexicon Pharmaceuticals announces $94.6M public offering for drug candidate R&D, Sanofi's Rezurock (belumosudil) receives CHMP approval recommendation for chronic graft-versus-host disease treatment
Biotech & Pharma Updates | January 28 - 29, 2026
🧬 AstraZeneca pledges $15B investment in China operations through 2030 for cell therapies and radioconjugates development, Roche wants to be in the “top three” in the obesity market with personalized weight-loss pipeline against Novo Nordisk & Eli Lilly, Agomab Therapeutics aims for $212M IPO to support immunology trials for Crohn's disease candidates, Breakthru Medicine emerges from stealth with $60M Series A for cancer drug development platform, Ascletis reports positive Ph3 safety results for denifanstat (ASC40) FASN inhibitor targeting acne vulgaris, Repertoire Immune Medicines + Eli Lilly collaborate on autoimmune tolerizing therapies with $85M upfront + $1.84B biobucks deal
Biotech & Pharma Updates | January 27 - 28, 2026
🧬 Eikon Therapeutics targets $274M IPO for four clinical-stage oncology candidates, Halozyme Therapeutics acquires Surf Bio for up to $400M to expand subcutaneous drug delivery portfolio, Cellares raises $257M Series D for cell therapy manufacturing platform expansion, Eli Lilly + Seamless Therapeutics partner on hearing loss gene editing platform worth over $1.12B, Antheia raises $24M Series C second close - biosynthetic drug ingredient manufacturing, Tenpoint Therapeutics receives FDA approval for YUVEZZI (carbachol and brimonidine tartrate) combination eye drop treating presbyopia
Biotech & Pharma Updates | January 26 - 27, 2026
🧬 TRexBio raises $50M Series B extension for testing eczema drug TRB-061, Boehringer Ingelheim + Simcere Pharmaceutical partner on IBD bispecific antibody SIM0709 for up to $1.26B total, Roche's CT-388 achieves 22.5% weight loss in Ph2 obesity trial - advancing to Ph3 development, Baseline Therapeutics launches to test GLP-1 drug BT-001 for alcohol use disorder - challenging Eli Lilly, EU and India agree to sweeping free trade pact eliminating 11% tariff on pharmaceutical exports, FDA lifts clinical hold on Intellia Therapeutics' MAGNITUDE-2 Phase III trial for ATTR gene editing treatment